| Potential Anticancer Effects of Diclofenac in Human Pancreatic Cancer Cells |
| Paper ID : 1311-IGA |
| Authors |
|
Mirela Tabaku * University of Medicine: Faculty of Medicine, Faculty of Dentistry.Tirana |
| Abstract |
| Background and Aim: Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive and lethal gastrointestinal malignancies, characterized by poor prognosis and limited therapeutic options. Diclofenac, a nonsteroidal anti-inflammatory drug (NSAID), has recently been investigated for its potential anticancer properties. This study aimed to evaluate the cytotoxic effects of diclofenac on human pancreatic cancer cells and to assess its potential as an adjuvant therapeutic candidate. Methods: An in vitro study was conducted using cultured human pancreatic carcinoma cells maintained in standard DMEM medium. The cells were treated with varying concentrations of diclofenac (31.25–500 µg/mL) for 24 hours. Cell viability was measured using the MTT assay, and the half-maximal inhibitory concentration (IC₅₀) was determined from the dose–response curve using GraphPad Prism software. Statistical analysis was performed using one-way ANOVA followed by Tukey’s post hoc test. Results: Diclofenac treatment significantly and dose-dependently reduced pancreatic cancer cell viability (P < 0.001). The IC₅₀ value was calculated to be 96 µg/mL, demonstrating a strong cytotoxic effect of diclofenac after 24 hours of exposure. Conclusion: Diclofenac exhibits significant cytotoxic and potential anticancer activity against human pancreatic carcinoma cells in vitro. These findings suggest its possible role as an adjuvant compound in pancreatic cancer therapy. Further mechanistic, preclinical, and clinical studies are warranted to confirm its therapeutic efficacy and safety. |
| Keywords |
| Pancreatic cancer, Diclofenac, Cytotoxicity, Human pancreatic carcinoma cells, Anticancer activity |
| Status: Accepted |
